Drug intelligence / Profile preview

MYL-1402O

Development stage: Phase 3
Lead developer: Viatris
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MYL-1402O is a biosimilar to bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). By binding to VEGF-A, it inhibits angiogenesis—the formation of new blood vessels—thereby restricting tumor growth and metastasis. MYL-1402O has demonstrated bioequivalence in pharmacokinetics, efficacy, safety, and immunogenicity compared to reference bevacizumab (Avastin) in clinical trials for advanced cancers such as non-squamous non-small cell lung cancer (nsNSCLC). It is developed through a partnership between Biocon Biologics and Mylan.

Brand names: AbevmyLextemy
Other names: bevacizumab biosimilarproposed bevacizumab biosimilar

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on MYL-1402O.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYL-1402O.

Explore the full profile